Bisantrene

Bisantrene is a highly effective antitumor agent, it exerts its cytotoxicity by affecting DNA intercalation. Bisantrene targets eukaryotic type II topoisomerases. Bisantrene is a substrate of MDR1[1][2][3][4].

Product Specifications

CAS Number

[78186-34-2]

Product Name Alternative

CL216942

UNSPSC

12352005

Hazard Statement

H302, H400

Target

Topoisomerase

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Bisantrene.html

Purity

98.06

Solubility

DMSO : 1 mg/mL (ultrasonic; warming; heat to 80°C) |H2O : < 0.1 mg/mL

Smiles

C12=CC=CC=C1C(/C=N/NC3=NCCN3)=C4C(C=CC=C4)=C2/C=N/NC5=NCCN5

Molecular Formula

C22H22N8

Molecular Weight

398.46

Precautions

H302, H400

References & Citations

[1]Sissi C, et al. DNA-binding preferences of Bisantrene analogues: relevance to the sequence specificity of drug-mediated topoisomerase II poisoning. Mol Pharmacol. 1998 Dec;54 (6) :1036-45.|[2]Yap HY, et al. Bisantrene, an active new drug in the treatment of metastatic breast cancer. Cancer Res. 1983 Mar;43 (3) :1402-4.|[3]Wang BS, et al. Activation of tumor-cytostatic macrophages with the antitumor agent 9,10-anthracenedicarboxaldehyde bis[ (4,5-dihydro-1H-imidazole-2-yl) hydrazone] dihydrochloride (bisantrene) . Cancer Res. 1984 Jun;44 (6) :2363-7. |[4]Aksentijevich I, et al. Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity. Clin Cancer Res. 1996 Jun;2 (6) :973-80.